Despite the significant public health issue that it poses, only five medical treatments have
been approved for Alzheimer's disease (AD) and these act to control symptoms rather than …

The foundation of current Alzheimer's disease (AD) treatment involves pharmacological and
nonpharmacological management and care planning predicated on patient-centered …

Although women experience significantly higher tau burden and increased risk for
Alzheimer's disease (AD) than men, the underlying mechanism for this vulnerability has not …

Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …

The elderly population is growing worldwide, with important health and socioeconomic
implications. Clinical and experimental studies on aging have uncovered numerous …

Alzheimer's disease (AD) is a progressive neurodegenerative disease, characterized by the
loss of memory, multiple cognitive impairments and changes in the personality and …

Alzheimer's disease (AD) is a multifactorial irreversible neurological disorder which results
in cognitive impairment, loss of cholinergic neurons in synapses of the basal forebrain and …

Alzheimer's disease (AD) is the most common cause of cognitive impairment or dementia in
individuals older than 65 years and, with rising longevity, a worldwide pandemic of mild …

This review describes the preclinical mechanisms that may underlie the increased
therapeutic benefit of combination therapy—with the N-methyl-d-aspartate receptor …

Alzheimer's disease (AD), once considered a rare disease, is now the most common form of
dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate …